You are here: Industry Insights > Boehringer Ingelheim

News List

ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology PharmaSources.com
January 10, 2023
ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology.
Evotec, Boehringer Ingelheim Partner to Tackle Ophthalmologic Disorders contractpharma
January 25, 2022
Aims to identify and validate promising targets and new approaches for therapeutic interventions.
Boehringer Ingelheim announces FDA acceptance of BLA for spesolimab Pharmaceutical-Business-Review
December 21, 2021
Boehringer Ingelheim has announced acceptance of a biologics license application (BLA) and granting of priority review by the US Food and Drug Administration (FDA) for spesolimab in treating generalized pustular psoriasis (GPP) flares.
EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements WorldPharmaNews
December 14, 2021
Boehringer Ingelheim announced that it will dedicate EUR 50 million to a new initiative called "Boehringer Ingelheim Social Engagements". The program provides financing for impact to social businesses in vulnerable communities through non-traditional...
GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients americanpharmaceuticalreview
August 10, 2021
GoodRx Inc., America’s leading resource for healthcare savings, and Boehringer Ingelheim, a privately owned, leading global biopharmaceutical company, announced a collaborative effort to increase access to patient savings programs on the GoodRx platform.
Columbia Clinic signed a cooperation agreement with Boehringer Ingelheim prnasia
August 04, 2021
On August 3rd, 2021, Columbia China, signed a cooperation agreement with Consanas Rehabilitation, brand of Boehringer Ingelheim.
Nanoform and Boehringer Ingelheim execute master services agreement prnasia
August 03, 2021
Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development p
Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry worldpharmanews
July 23, 2021
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF pharmatimes
July 07, 2021
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF).
Aragen Expands Discovery Research Agreement with Boehringer Ingelheim contractpharma
July 02, 2021
Aragen Life Sciences is expanding its discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page